BNP Paribas Financial Markets Acquires New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

BNP Paribas Financial Markets acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,860 shares of the company's stock, valued at approximately $1,230,000.

A number of other hedge funds have also recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HIMS shares. Leerink Partners increased their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $61.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Citigroup reaffirmed a "sell" rating and set a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Morgan Stanley lowered their target price on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $37.67.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the sale, the insider now owns 193,601 shares of the company's stock, valued at approximately $9,319,952.14. This trade represents a 8.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the sale, the chief executive officer now directly owns 89,311 shares in the company, valued at approximately $5,215,762.40. The trade was a 58.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold 618,936 shares of company stock worth $25,182,692 over the last 90 days. 13.71% of the stock is owned by insiders.

Hims & Hers Health Stock Down 3.6%

Shares of Hims & Hers Health stock opened at $62.35 on Tuesday. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The company has a 50 day moving average of $36.01 and a 200 day moving average of $34.19. The company has a market capitalization of $13.96 billion, a P/E ratio of 141.71 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the previous year, the firm earned $0.05 earnings per share. The firm's quarterly revenue was up 110.7% on a year-over-year basis. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.